Analysis on the characteristics and influencing factors of peripheral neurotoxicity induced by antibody-drug conjugate disitamab vedotin
YIN Yue
ZHANG Yan-hua
Abstract：Objective:To investigate neurotoxicity's occurrence and influencing factors in tumor patients treated with antibody-drug conjugate(ADC)disitamab vedotin,providing evidence for individualized drug administration.Methods:The cases of patients treated with disitamab vedotin in our hospital from January 2020 to June 2023 were collected,and the clinical information of the patients was recorded.Retrospective analysis,univariate analysis and regression analysis were used to determine the influencing factors of neurotoxicity induced by disitamab vedotin.Results:A total of 137 patients who underwent the treatment of disitamab vedotin were included in this study.Among the patients,37 cases appeared neurotoxicity,accounting for 27.01％,in which insensitive hands and feet in 16 cases(11.7％),limbs arthralgia and myalgia with numbness and tingling in 23 cases(16.8％),decreased muscle strength in 13 cases(9.5％),walking difficult 6 cases(4.4％).In this study,the onset time of neurotoxicity ranged from 3 days to 241 days after treatment,and the median time was 42 days after treatment.About 50％of patients developed neurological toxicity after 2 cycles of treatment.Univariate and multivariate regression analysis showed that gender,age,BMI,ECOG score and history of comorbidities had statistically significant effects on neurotoxicity(P＜0.05),and history of comorbidities(OR=10.125,95％CI:3.194～32.101,P＜0.001)and age(OR=2.802,95％CI:1.137～6.908,P=0.025)were independent risk factors for neurotoxicity after disitamab vedotin treatment(OR＞1,P＜0.05).Conclusion:Previous disease and age are the factors influencing neurotoxicity after disitamab vedotin treatment.Therefore,when using the antibody-drug conjugate(ADC)disitamab vedotin,it is necessary to pay close attention to the occurrence of neurotoxicity and preventive intervention measures should be actively taken for patients over 60 years old with previous underlying diseases such as hypertension and diabetes.
Keywords：peripheral neuropathyantibody-drug conjugatedisitamab vedotinanalysis of influencing factors
Publication Date：2024-08-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 1608-1614 )